Thyrocare Technologies Limited announced several key outcomes from its Board Meeting held on May 07, 2026. The Board recommended a final dividend of ₹7.00 per equity share for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM). This, combined with the interim dividend of ₹7.00 per equity share already paid (post-bonus adjustment equivalent to ₹2.33 per share), brings the total dividend for FY2025-26 to ₹9.33 per equity share. In terms of corporate governance and auditing, the Board approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP as the Statutory Auditors for a five-year term, commencing from the conclusion of the 26th AGM in 2026 until the 31st AGM in 2031. M/s. Jitender Navneet & Co. were appointed as Cost Auditors for the financial year 2026-27. Significant changes in directorship were also noted. Mr. Rahul Franklin Guha was re-appointed as Chairman, Managing Director & CEO for a five-year term from May 04, 2027, to May 03, 2032, subject to shareholder approval. Mr. Uday Patel Kadam and Mr. Gaurav Verma were appointed as Additional Directors (Non-Executive, Non-Independent) effective May 08, 2026. Concurrently, the Board accepted the resignations of Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah, Non-Executive, Non-Independent Directors, both effective May 07, 2026, due to pre-occupation and other commitments. Strategically, the company approved an investment of up to ₹5.50 crore in the equity shares of Think Health Diagnostics Private Limited, its wholly-owned subsidiary, to support its business operations and capital requirements. The Memorandum of Association (MOA) of the company was also approved for alteration to align with the Companies Act, 2013, and broaden the scope of its healthcare and diagnostics business activities. The Board Meeting commenced at 3:35 PM and concluded at 5:40 PM.
